Peptide receptor radionuclide therapy is a type of next generation drug conjugate, which uses peptide as the targeting ligand, and radionuclide as their cytotoxic payload, to provide targeted therapy. Lutathera by Advanced Accelerator Applications was the first peptide receptor radionuclide therapy to be approved by the USFDA and the EMA for the treatment of neuroendocrine tumor.